01Dec
Americas Antitrust Review 2021
Covid-19 has made 2020 into a year like no other with ‘stay at home’ orders and working from home the new normal. Nonetheless, the tech and pharma industries continued to attract immense antitrust scrutiny, with daily reports in the media and pressure from politicians to address what some perceive to be anticompetitive mergers by digital platforms and pharmaceutical companies, even while innovation in both sectors continues at breakneck speed. In this article, we discuss some of the most...
By:
Cooley LLP
Related
Turning a blind eye – one-off act not a PCP - In Ishola v Transport for London the Court of Appeal...
Read More >
1. The National Labor Relations Board (NLRB) has clarified its standard for evaluating the legality ...
Read More >
In Illinois, a shareholder has the right to dissent from certain corporate actions such as a merger,...
Read More >
Disclosure-only settlements of M&A class actions have received increased scrutiny since decisions li...
Read More >
The COVID-19 pandemic is causing disruption to a wide range of industries and construction in the he...
Read More >
On September 9, 2019, the Treasury Department (Treasury) and the Internal Revenue Service (IRS) prop...
Read More >